PHOENIX — A recent study reveals a new combination of drugs is showing promise in fighting pancreatic cancer. Led by Scottsdale Healthcare and Translations Genomics Research Institute in Phoenix, the ...

The trial is investigating the Company's best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane® in patients with metastatic pancreatic ...

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer Patients with ...

The word "cancer" is scary regardless of the type, but few types of cancer are as lethal as pancreatic cancer. Based on estimates from the American Cancer Society in 2013, an estimated 45,220 people ...

IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...

(Reuters) - Celgene Corp said on Friday that a clinical trial of Abraxane, its drug to treat breast and lung cancer, improved survival in patients with pancreatic cancer. The company did not give ...

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile. Atebimetinib (IMM-1-104) in combination with ...

(Reuters) - U.S. regulators on Friday approved use of Celgene Corp's Abraxane to treat patients with pancreatic cancer that has spread to other parts of the body, citing a trial that showed the drug ...

Amplia Therapeutics (ASX:ATX) has popped over +40% in lunchtime trades as the company reports its products provide superior outcomes when coupled with chemotherapy, at least in one ‘ACCENT’ trial ...